SHORT MINI FUTURE - ELI LILLY & CO | Market Closed - Swiss Exchange 11:20:00 2024-07-04 am EDT | ||
| 1.15 CHF | -5.74% |
|
| Current month | +10.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 1.15 | -5.74% |
| 24-07-03 | 1.22 | +7.02% |
| 24-07-02 | 1.14 | +12.87% |
| 24-07-01 | 1.01 | -2.88% |
| 24-06-28 | 1.04 | -7.96% |
Delayed Quote Swiss Exchange
Last update July 04, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| MLLAJV | |
| ISIN | CH1349591102 |
| Date issued | 2024-06-05 |
| Strike | 1,027 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 1.79 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.67 CHF |
|---|---|
| Lowest since issue | 1.01 CHF |
| Spread | 0.03 CHF |
| Spread % | 2.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Certificates
- MLLAJV Certificat
